title: Dopaminergic agonists that result in ocular growth inhibition also elicit transient increases in choroidal thickness in chicks.
abstract: The dopaminergic system has been implicated in ocular growth regulation in chicks and monkeys. In both, dopamine D2 agonists inhibit the development of myopia in response to form deprivation, and in chicks, to negative lenses as well. Because there is mounting evidence that the choroidal response to defocus plays a role in ocular growth regulation, we asked whether the effective agonists also elicit transient thickening of the choroid concomitant with the growth inhibition. Negative lenses mounted on velcro rings were worn on one eye starting at age 8-12 days. Intravitreal injections (20 μl; dose = 10 nmole) of the agonist (dissolved in saline) or saline, were given through the superior temporal sclera using a 30G needle. Eyes were injected daily at noon, for 4 days, and the lenses immediately replaced. Agonists used were apomorphine (non-specific; n = 17), quinpirole (D2; n = 10), SKF-38393 (D1; n = 9), and saline controls (n = 22). For the antagonists, the same protocol was used, but on each day, the lenses were removed for 2 h. Immediately prior to lens-removal, the antagonist was injected (20 μl; dose = 5 nmole). Antagonists used were methylergonovine (non-specific; n = 12), spiperone (D2; n = 20), SCH-23390 (D1; n = 6) and saline controls (n = 27). Comparisons to saline (continuous lens wear) controls were from the agonist experiment. Axial dimensions were measured using high frequency A-scan ultrasonography at the start of lens wear, and on day 4 prior to the injections, and then again 3 h later. Refractive errors were measured using a Hartinger's refractometer at the end of the experiment. Apomorphine and quinpirole inhibited the refractive response to the hyperopic defocus induced by the negative lenses (drug vs saline controls: -1.3 and 1.2 D vs -5.6 D; p < 0.005 for both). This effect was axial: both drugs prevented the excessive ocular elongation (change in axial length: 233 and 205 μm vs 417 μm; p < 0.01 for both). Both drugs were also associated with a transient thickening of the choroid over 3 h (41 and 32 μm vs -1 μm; p < 0.01; p = 0.059 respectively) that did not summate: choroids thinned significantly over the 4 day period in all lens-wearing eyes. Two daily hours of unrestricted vision during negative lens wear normally prevents the development of myopia. Spiperone and SCH-23390 inhibited the ameliorating effects of periods of vision on lens-induced refractive error (-2.9 and -2.8 D vs 0.6 D; p < 0.0001), however, the effects on neither axial length nor choroidal thickness were significant. These data support a role for both D1 and D2 receptors in the ocular growth responses.
authors.affiliation: The New England College of Optometry, Dept. of Biosciences, 424 Beacon St., Boston, MA 02115, USA. nicklad@neco.edu
authors.forename: Debora L
authors.initials: DL
authors.lastname: Nickla
authors.forename: Kristen
authors.initials: K
authors.lastname: Totonelly
authors.forename: Balprit
authors.initials: B
authors.lastname: Dhillon
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001058:Apomorphine / Q000494:pharmacology; D002645:Chickens; D002829:Choroid / Q000187:drug effects* / Q000473:pathology; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D005123:Eye / Q000254:growth & development* / Q000378:metabolism; D005139:Eyeglasses; D006984:Hypertrophy; D007267:Injections; D009216:Myopia / Q000517:prevention & control*; D019257:Quinpirole / Q000494:pharmacology; D017447:Receptors, Dopamine D1 / Q000819:agonists; D017448:Receptors, Dopamine D2 / Q000819:agonists; D012029:Refraction, Ocular / Q000187:drug effects*; D014822:Vitreous Body
chemical_list: D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D019257:Quinpirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D001058:Apomorphine
references.citation: Optom Vis Sci. 2010 Jan;87(1):53-60
references.pmid: 19901858
references.citation: Nature. 1978 Aug 3;274(5670):513-4
references.pmid: 672981
references.citation: Prog Retin Eye Res. 2010 Mar;29(2):144-68
references.pmid: 20044062
references.citation: Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1329-35
references.pmid: 16550409
references.citation: Invest Ophthalmol Vis Sci. 1991 Apr;32(5):1674-7
references.pmid: 2016144
references.citation: Vis Neurosci. 1991 Nov;7(5):451-8
references.pmid: 1764415
references.citation: Exp Eye Res. 2007 Jan;84(1):100-7
references.pmid: 17094962
references.citation: Eur J Neurosci. 1996 Nov;8(11):2286-97
references.pmid: 8950093
references.citation: Neuropharmacology. 2003 Jun;44(8):1038-46
references.pmid: 12763097
references.citation: Optom Vis Sci. 2004 Feb;81(2):111-8
references.pmid: 15127930
references.citation: Curr Eye Res. 1997 Feb;16(2):152-7
references.pmid: 9068946
references.citation: Proc Natl Acad Sci U S A. 1989 Jan;86(2):704-6
references.pmid: 2911600
references.citation: Vis Neurosci. 1997 Mar-Apr;14(2):351-6
references.pmid: 9147486
references.citation: Ciba Found Symp. 1990;155:45-57; discussion 57-62
references.pmid: 2088680
references.citation: J Comp Neurol. 1978 Jul 15;180(2):203-20
references.pmid: 207745
references.citation: Neuropharmacology. 1977 Sep;16(9):549-56
references.pmid: 21357
references.citation: Exp Eye Res. 2007 May;84(5):951-9
references.pmid: 17395180
references.citation: Invest Ophthalmol. 1971 Jun;10(6):438-52
references.pmid: 4325307
references.citation: Vis Neurosci. 1993 May-Jun;10(3):447-53
references.pmid: 8494798
references.citation: Exp Eye Res. 2009 Jun;88(6):1092-9
references.pmid: 19450449
references.citation: Vis Neurosci. 1994 Mar-Apr;11(2):199-208
references.pmid: 8003448
references.citation: Trends Pharmacol Sci. 1994 Jul;15(7):264-70
references.pmid: 7940991
references.citation: Vision Res. 1994 Jan;34(2):143-9
references.pmid: 8116274
references.citation: Eur J Neurosci. 1997 May;9(5):1096-100
references.pmid: 9182963
references.citation: Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5247-53
references.pmid: 20445123
references.citation: Invest Ophthalmol Vis Sci. 2001 Mar;42(3):575-83
references.pmid: 11222513
references.citation: Vision Res. 1987;27(7):1139-63
references.pmid: 3660666
references.citation: Eur J Neurosci. 2005 Apr;21(8):2199-208
references.pmid: 15869516
references.citation: Curr Eye Res. 2006 Jan;31(1):91-105
references.pmid: 16421023
references.citation: Neuroscience. 1998 Apr;83(3):781-9
references.pmid: 9483561
references.citation: Exp Eye Res. 1998 Feb;66(2):163-81
references.pmid: 9533843
references.citation: Doc Ophthalmol. 2004 Jan;108(1):17-40
references.pmid: 15104164
references.citation: Vision Res. 1997 Mar;37(6):659-68
references.pmid: 9156210
references.citation: Vision Res. 1995 May;35(9):1247-64
references.pmid: 7610585
references.citation: Curr Eye Res. 1995 May;14(5):385-9
references.pmid: 7648864
references.citation: Cell Mol Neurobiol. 1990 Sep;10(3):303-25
references.pmid: 2174740
references.citation: Vision Res. 1995 May;35(9):1175-94
references.pmid: 7610579
references.citation: Brain Res. 1995 Oct 16;695(2):110-6
references.pmid: 8556320
references.citation: Optom Vis Sci. 2004 Feb;81(2):137-47
references.pmid: 15127933
references.citation: Ophthalmology. 2008 Aug;115(8):1279-85
references.pmid: 18294691